On January 11, 2024, BioMarin Pharmaceutical Inc. announced that Mr. Jeffrey Ajer would step down as the Company?s Executive Vice President and Chief Commercial Officer, effective July 1, 2024. Mr. Ajer?s compensation will remain unchanged through that date. The separation will constitute a termination of employment by the Company without cause under Mr. Ajer?s Amended and Restated Employment Agreement dated June 10, 2015 (the ?Employment Agreement?), and as such, Mr. Ajer will be entitled to receive severance pursuant to the Employment Agreement.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
80.91 USD | -1.53% | -8.71% | -16.09% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.09% | 15.36B | |
-4.66% | 86.13B | |
+1.32% | 39.82B | |
-19.27% | 30.42B | |
+57.86% | 25.23B | |
-9.14% | 11.95B | |
-17.69% | 11.6B | |
-43.00% | 11.51B | |
+5.24% | 8.71B | |
-8.42% | 8.12B |
- Stock Market
- Equities
- BMRN Stock
- News BioMarin Pharmaceutical Inc.
- Biomarin Pharmaceutical Inc. Announces Resignation of Jeffrey Ajer as Executive Vice President and Chief Commercial Officer, Effective from July 1, 2024